Glioblastoma pp 299-323 | Cite as

Current Endeavors for Enhancing Efficacy of Paclitaxel for Treatment of Glioblastoma

  • Surajit Karmakar
  • Naren L. Banik
  • Swapan K. Ray
Chapter
First Online:

Abstract

Paclitaxel, the plant-derived anticancer drug, has shown clinical efficacy against a wide variety of solid tumors such as breast cancer, ovarian cancer, nonsmall-cell lung cancer, and melanoma. The antineoplastic effect of paclitaxel is attributed to cell cycle arrest at G2/M phase and microtubule stabilization leading to activation of apoptosis. The use of paclitaxel in glioblastoma, which is a devastating brain tumor, is still limited and thus this is an emerging area to explore the strategies for using paclitaxel for the treatment of glioblastoma. A limited number of studies showed that paclitaxel possessed the potential to treat glioblastoma, but there were few concerns that limited its use in brain tumor. This chapter will focus on the current research that indicates how to overcome the difficulties and promising prospect of using paclitaxel in glioblastoma in the future.

Keywords

Apoptosis Combination therapy Enhancing efficacy Glioblastoma Paclitaxel 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported in part by the R01 grants (CA-91460 and NS-57811) from the National Institutes of Health (Bethesda, MD) to S.K.R.

References

  1. Allen JN, Moore SA, Wewers MD (1993) Taxol enhances but does not induce interleukin-1β and tumor necrosis factor-alpha production. J Lab Clin Med 122:374–381PubMedGoogle Scholar
  2. Altznauer F, Conus S, Cavalli A, Folkers G, Simon HU (2004) Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis. J Biol Chem 279:5947–5957PubMedCrossRefGoogle Scholar
  3. Amos B, Lotan R (1990) Retinoid-sensitive cells and cell lines. Methods Enzymol 190:217–225PubMedCrossRefGoogle Scholar
  4. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, Walle T (1995) Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos 23:1286–1290PubMedGoogle Scholar
  5. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R (2001) Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20:147–155PubMedCrossRefGoogle Scholar
  6. Banks WA (1999) Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol 5:538–555PubMedCrossRefGoogle Scholar
  7. Bhadra D, Bhadra S, Jain S, Jain NK (2003) A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 257:111–124PubMedCrossRefGoogle Scholar
  8. Biswas KK, Tancharoen S, Sarker KP, Kawahara K, Hashiguchi T, Maruyama I (2006) Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt. FEBS Lett 580:703–710PubMedCrossRefGoogle Scholar
  9. Blagosklonny MV, Fojo T (1999) Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83:151–156PubMedCrossRefGoogle Scholar
  10. Bogdan C, Ding A (1992) Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52:119–121PubMedGoogle Scholar
  11. Burton E, Prados M (1999) New chemotherapy options for the treatment of malignant gliomas. Curr Opin Oncol 11:157–161PubMedCrossRefGoogle Scholar
  12. Cahan MA, Walter KA, Colvin OM, Brem H (1994) Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33:441–444PubMedCrossRefGoogle Scholar
  13. Chamberlain MC, Kormanik P (1999) Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol 43:71–78PubMedCrossRefGoogle Scholar
  14. Choi YH (2006) Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity. Int J Oncol 29:1207–1213PubMedGoogle Scholar
  15. Cregan SP, Fortin A, MacLaurin JG, Callaghan SM, Cecconi F, Yu SW, Dawson TM, Dawson VL, Park DS, Kroemer G, Slack RS (2002) Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol 158:507–517PubMedCrossRefGoogle Scholar
  16. Das A, Banik NL, Ray SK (2007) Differentiation decreased telomerase activity in rat glioblastoma C6 cells and increased sensitivity to IFN-gamma and taxol for apoptosis. Neurochem Res 32:2167–2183PubMedCrossRefGoogle Scholar
  17. Das A, Banik NL, Ray SK (2008) Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 87:9–22PubMedCrossRefGoogle Scholar
  18. Deeken JF, Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663–1674PubMedCrossRefGoogle Scholar
  19. DePinho RA (2000) The age of cancer. Nature 408:248–254PubMedCrossRefGoogle Scholar
  20. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedCrossRefGoogle Scholar
  21. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324; erratum in Clin Cancer Res 12:3869Google Scholar
  22. Ding AH, Porteu F, Sanchez E, Nathan CF (1990) Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 48:370–372CrossRefGoogle Scholar
  23. Dragnev KH, Rigas JR, Dmitrovsky E (2000) The retinoids and cancer prevention mechanisms. Oncologist 5:361–368PubMedCrossRefGoogle Scholar
  24. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33–42PubMedCrossRefGoogle Scholar
  25. Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, Kujawa JM, Young D, Egorin MJ (1994) Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465–471PubMedCrossRefGoogle Scholar
  26. Eitel K, Wagenknecht B, Weller M (1999) Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. Cancer Lett 142:11–16PubMedCrossRefGoogle Scholar
  27. Ettinger DS (1993) Taxol in the treatment of lung cancer. J Natl Cancer Inst Monogr 15:177–179PubMedGoogle Scholar
  28. Fan W (1999) Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57:1215–1221PubMedCrossRefGoogle Scholar
  29. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A, Fricker G (2002) Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309–1318PubMedGoogle Scholar
  30. Fleming AB, Saltzman WM (2002) Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 41:403–419PubMedCrossRefGoogle Scholar
  31. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M (2005) Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 103:2606–2615PubMedCrossRefGoogle Scholar
  32. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590–1598PubMedCrossRefGoogle Scholar
  33. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803PubMedCrossRefGoogle Scholar
  34. Guo JM, Xiao BX, Kang GZ, Liu DH, Chen H, Zhang S, Zhang XN (2006) Suppression of telomerase activity and arrest at G1 phase in human cervical cancer HeLa cells by all-trans retinoic acid. Int J Gynecol Cancer 16:341–346PubMedCrossRefGoogle Scholar
  35. Gupta S (2002) Tumor necrosis factor-alpha-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules. Exp Gerontol 37:293–299PubMedCrossRefGoogle Scholar
  36. Haldar S, Jena N, Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507–4511PubMedCrossRefGoogle Scholar
  37. Haque A, Das A, Hajiaghamohseni LM, Younger A, Banik NL, Ray SK (2007) Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol Immunother 56:615–625PubMedCrossRefGoogle Scholar
  38. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, Beijnen JH (1994) Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 5:951–953PubMedGoogle Scholar
  39. Helson L, Helson C, Malik S, Ainsworth S, Mangiardi J (1993) A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drugs 4:487–490PubMedCrossRefGoogle Scholar
  40. Ho SY, Barbarese E, D’Arrigo JS, Smith-Slatas C, Simon RH (1997) Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in brain tumor therapy. Neurosurgery 40:1260–1266PubMedCrossRefGoogle Scholar
  41. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805PubMedGoogle Scholar
  42. Hormi-Carver K, Feagins LA, Spechler SJ, Souza RF (2007) All trans-retinoic acid induces apoptosis via p38 and caspase pathways in metaplastic Barrett’s cells. Am J Physiol Gastrointest Liver Physiol 292:G18–G27PubMedCrossRefGoogle Scholar
  43. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH (1995) Taxanes: a new class of antitumor agents. Cancer Invest 13:381–404PubMedCrossRefGoogle Scholar
  44. Ji ZN, Ye WC, Liu GG, Hsiao WL (2002) 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 Cells. Life Sci 72:1–9PubMedCrossRefGoogle Scholar
  45. Joo KM, Park K, Kong DS, Song SY, Kim MH, Lee GS, Kim MS, Nam DH (2008) Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor. Oncol Rep 19:17–23PubMedGoogle Scholar
  46. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265PubMedCrossRefGoogle Scholar
  47. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162PubMedCrossRefGoogle Scholar
  48. Karmakar S, Weinberg MS, Banik NL, Patel SJ, Ray SK (2006) Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience 141:1265–1280PubMedCrossRefGoogle Scholar
  49. Karmakar S, Banik NL, Patel SJ, Ray SK (2007) Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis 12:2077–2087PubMedCrossRefGoogle Scholar
  50. Karmakar S, Banik NL, Ray SK (2008) Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer 112:596–607PubMedCrossRefGoogle Scholar
  51. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O (2003) Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9:2849–2855PubMedGoogle Scholar
  52. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O (2004) Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 30:415–423PubMedCrossRefGoogle Scholar
  53. Kim R (2005) Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103:1551–1560PubMedCrossRefGoogle Scholar
  54. Koga H, Inamura T, Ikezaki K, Nomura T, Samoto K, Fukui M (1996) Increased delivery of a new cisplatin analogue (254-S) in a rat brain tumor by an intracarotid infusion of bradykinin. Neurol Res 18:244–247PubMedGoogle Scholar
  55. Korhonen L, Hansson I, Kukkonen JP, Brännvall K, Kobayashi M, Takamatsu K, Lindholm D (2005) Hippocalcin protects against caspase-12-induced and age-dependent neuronal degeneration. Mol Cell Neurosci 28:85–95PubMedCrossRefGoogle Scholar
  56. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99:259–269PubMedCrossRefGoogle Scholar
  57. Koziara JM, Whisman TR, Tseng MT, Mumper RJ (2006) In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 112:312–319PubMedCrossRefGoogle Scholar
  58. Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6:513–519PubMedCrossRefGoogle Scholar
  59. Lee LF, Li G, Templeton DJ, Ting JP (1998) Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273:28253–28260PubMedCrossRefGoogle Scholar
  60. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479–489PubMedCrossRefGoogle Scholar
  61. Li KW, Dang W, Tyler BM, Troiano G, Tihan T, Brem H, Walter KA (2003) Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 9:3441–3447PubMedGoogle Scholar
  62. Linskey ME, Gilbert MR (1995) Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery 36:1–21; discussion 21–22Google Scholar
  63. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G (2000) Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells. J Biol Chem 275:3081–3087PubMedCrossRefGoogle Scholar
  64. MacKeigan JP, Taxman DJ, Hunter D, Earp HS III, Graves LM, Ting JP (2002) Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8:2091–2099Google Scholar
  65. Manfredi JJ, Parness J, Horwitz SB (1982) Taxol binds to cellular microtubules. J Cell Biol 94:688–696PubMedCrossRefGoogle Scholar
  66. Mangelsdorf DJ, Umesono K, Evans RM (1994) The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS (eds) The retinoids: biology chemistry and medicine, 2nd edn. Raven Press, New York, pp 319–349Google Scholar
  67. Manthey CL, Qureshi N, Stütz PL, Vogel SN (1993) Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages. J Exp Med 178:695–702PubMedCrossRefGoogle Scholar
  68. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6:609–621PubMedCrossRefGoogle Scholar
  69. Massard C, Zermati Y, Pauleau AL, Larochette N, Métivier D, Sabatier L, Kroemer G, Soria JC (2006) hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway. Oncogene 25:4505–4514PubMedCrossRefGoogle Scholar
  70. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279PubMedGoogle Scholar
  71. Merino R, Hurlé JM (2003) The molecular basis of retinoid action in tumors. Trends Mol Med 9:509–511PubMedCrossRefGoogle Scholar
  72. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K (2006) Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 317:1246–1253PubMedCrossRefGoogle Scholar
  73. Mohamed AA, Jupp OJ, Anderson HM, Littlejohn AF, Vandenabeele P, MacEwan DJ (2002) Tumour necrosis factor-induced activation of c-Jun N-terminal kinase is sensitive to caspase-dependent modulation while activation of mitogen-activated protein kinase (MAPK) or p38 MAPK is not. Biochem J 366(part 1):145–155Google Scholar
  74. Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413–450PubMedCrossRefGoogle Scholar
  75. Nehmé A, Varadarajan P, Sellakumar G, Gerhold M, Niedner H, Zhang Q, Lin X, Christen RD (2001) Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells. Br J Cancer 84:1571–1576PubMedCrossRefGoogle Scholar
  76. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381–395PubMedCrossRefGoogle Scholar
  77. Nimmanapalli R, Perkins CL, Orlando M, O’Bryan E, Nguyen D, Bhalla KN (2001) Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61:759–763PubMedGoogle Scholar
  78. Oh-hashi K, Kaneyama M, Hirata Y, Kiuchi K (2006) ER calcium discharge stimulates GDNF gene expression through MAPK-dependent and -independent pathways in rat C6 glioblastoma cells. Neurosci Lett 405:100–105PubMedCrossRefGoogle Scholar
  79. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609–619PubMedCrossRefGoogle Scholar
  80. Panyam J, Labhasetwar V (2004) Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 1:77–84PubMedCrossRefGoogle Scholar
  81. Pardridge WM (1997) Drug delivery to the brain. J Cereb Blood Flow Metab 17:713–731PubMedCrossRefGoogle Scholar
  82. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3–14PubMedCrossRefGoogle Scholar
  83. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR (2004) Taxol induces caspase-10-dependent apoptosis. J Biol Chem 279:51057–51067PubMedCrossRefGoogle Scholar
  84. Parney IF, Chang SM (2005) Current chemotherapy for glioblastoma. In: Markert J, DeVita VT Jr, Rosenberg SA, Hellman S (eds) Glioblastoma multiforme, 1st edn. Jones and Bartlett, Sudbury, MA, pp 161–177Google Scholar
  85. Polster BM, Basañez G, Etxebarria A, Hardwick JM, Nicholls DG (2005) Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 280:6447–6454PubMedCrossRefGoogle Scholar
  86. Pradilla G, Wang PP, Gabikian P, Li K, Magee CA, Walter KA, Brem H (2006) Local intracerebral administration of Paclitaxel with the paclimer delivery system: toxicity study in a canine model. J Neurooncol 76:131–138PubMedCrossRefGoogle Scholar
  87. Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Kuhn J, Lamborn K, Rector DJ, Chang SM (1996) Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14:2316–2321PubMedGoogle Scholar
  88. Rao RV, Castro-Obregon S, Frankowski H, Schuler M, Stoka V, del Rio G, Bredesen DE, Ellerby HM (2002) Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem 277:21836–21842PubMedCrossRefGoogle Scholar
  89. Raymond JJ, Robertson DM, Dinsdale HB (1986) Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci 13:214–220PubMedGoogle Scholar
  90. Rice A, Liu Y, Michaelis ML, Himes RH, Georg GI, Audus KL (2005) Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. J Med Chem 48:832–838PubMedCrossRefGoogle Scholar
  91. Riondel J, Jacrot M, Fessi H, Puisieux F, Potier P (1992) Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo 6:23–27Google Scholar
  92. Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M (1998) Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br J Cancer 77:404–411PubMedCrossRefGoogle Scholar
  93. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093–4100PubMedGoogle Scholar
  94. Sakahira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391:96–99PubMedCrossRefGoogle Scholar
  95. Salah-Eldin AE, Inoue S, Tsukamoto S, Aoi H, Tsuda M (2003) An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment. Int J Cancer 103:53–60PubMedCrossRefGoogle Scholar
  96. Scarlett JL, Sheard PW, Hughes G, Ledgerwood EC, Ku HH, Murphy MP (2000) Changes in mitochondrial membrane potential during staurosporine-induced apoptosis in Jurkat cells. FEBS Lett 475:267–272PubMedCrossRefGoogle Scholar
  97. Schiff PB, Horwitz SB (1981) Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 20:3247–3252PubMedCrossRefGoogle Scholar
  98. Sergeev IN (2004) Genistein induces Ca2+ -mediated, calpain/caspase-12-dependent apoptosis in breast cancer cells. Biochem Biophys Res Commun 321:462–467PubMedCrossRefGoogle Scholar
  99. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40 suppl:S13–S19Google Scholar
  100. Silbergeld DL, Chicoine MR, Madsen CL (1995) In vitro assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion. Anticancer Drugs 6:270–276PubMedCrossRefGoogle Scholar
  101. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO (2001) Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61:6674–6678PubMedGoogle Scholar
  102. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759–767PubMedCrossRefGoogle Scholar
  103. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018PubMedCrossRefGoogle Scholar
  104. Sun J, Huang H, Zhu Y, Lan J, Li J, Lai X, Yu J (2005) The expression of telomeric proteins and their probable regulation of telomerase during the differentiation of all-trans-retinoic acid-responsive and -resistant acute promyelocytic leukemia cells. Int J Hematol 82:215–223PubMedCrossRefGoogle Scholar
  105. Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2:16PubMedCrossRefGoogle Scholar
  106. Tarr BD, Yalkowsky SH (1987) A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J Parenter Sci Technol 41:31–33PubMedGoogle Scholar
  107. Tascos NA, Parr J, Gonatas NK (1982) Immunocytochemical study of the glial fibrillary acidic protein in human neoplasms of the central nervous system. Hum Pathol 13:454–458PubMedCrossRefGoogle Scholar
  108. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, Arnold H, Gundersen G (1997) Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75:1744–1752PubMedCrossRefGoogle Scholar
  109. Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, Beers S, Goodin S, Rubin E, DiPaola RS (2003) A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol 52:119–124PubMedCrossRefGoogle Scholar
  110. Tseng SH, Bobola MS, Berger MS, Silber JR (1999) Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. Neuro Oncol 1:101–108PubMedGoogle Scholar
  111. Tsujimoto Y (2003) Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 195:158–167PubMedCrossRefGoogle Scholar
  112. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972PubMedGoogle Scholar
  113. Tudor G, Aguilera A, Halverson DO, Laing ND, Sausville EA (2000) Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 7:574–586PubMedCrossRefGoogle Scholar
  114. Vaishampayan U, Flaherty L, Du W, Hussain M (2001) Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 92:519–523PubMedCrossRefGoogle Scholar
  115. van Asperen J, Mayer U, van Tellingen O, Beijnen JH (1997) The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86:881–884PubMedCrossRefGoogle Scholar
  116. Veal GJ, Errington J, Redfern CP, Pearson AD, Boddy AV (2002) Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochem Pharmacol 63:207–215PubMedCrossRefGoogle Scholar
  117. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B, Daniel PT (2003) Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 22:2236–2247CrossRefGoogle Scholar
  118. Wang CY, Mayo MW, Baldwin AS Jr (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274:784–787PubMedCrossRefGoogle Scholar
  119. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr (1998) NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683PubMedCrossRefGoogle Scholar
  120. Wang LG, Liu XM, Kreis W, Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355–361PubMedCrossRefGoogle Scholar
  121. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:39435–39443PubMedCrossRefGoogle Scholar
  122. Wang PP, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Deliv Rev 54:987–1013PubMedCrossRefGoogle Scholar
  123. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327PubMedCrossRefGoogle Scholar
  124. Warner HR (1997) Aging and regulation of apoptosis. Curr Top Cell Regul 35:107–121PubMedCrossRefGoogle Scholar
  125. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268PubMedGoogle Scholar
  126. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMedGoogle Scholar
  127. White CM, Martin BK, Lee LF, Haskill JS, Ting JP (1998) Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother 46:104–112PubMedCrossRefGoogle Scholar
  128. Witcher M, Ross DT, Rousseau C, Deluca L, Miller WH Jr (2003) Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. Blood 102:237–245PubMedCrossRefGoogle Scholar
  129. Xia L, Wurmbach E, Waxman S, Jing Y (2006) Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia 20:1009–1016PubMedCrossRefGoogle Scholar
  130. Yacoub A, Han SI, Caron R, Gilfor D, Mooberry S, Grant S, Dent P (2003) Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 2:670–676PubMedGoogle Scholar
  131. Yamini B, Yu X, Gillespie GY, Kufe DW, Weichselbaum RR (2004) Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res 64:6381–6384PubMedCrossRefGoogle Scholar
  132. Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA (1994) Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol 127:23–36PubMedCrossRefGoogle Scholar
  133. Yoo HS, Lee KH, Oh JE, Park TG (2000) In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Control Release 68:419–431PubMedCrossRefGoogle Scholar
  134. Yu Z, Xing Y (2006) ATRA-induced apoptosis of mouse embryonic palate mesenchymal cells involves activation of MAPK pathway. Toxicol Appl Pharmacol 215:57–63PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Surajit Karmakar
  • Naren L. Banik
  • Swapan K. Ray
    • 1
  1. 1.Department of Pathology, Microbiology, and ImmunologyUniversity of South Carolina School of MedicineColumbiaUSA

Personalised recommendations